Objective. Molecular medicine raised expectations for strategically targeted biologic agents in systemic lupus erythematosus (SLE), but clinical trial results have been disappointing and difficult to interpret. Most studies add investigational agents to various, often effective, standard therapy immunosuppressants used at baseline, with unknown treatment interactions. Eliminating polypharmacy in trials of active lupus remains controversial. We undertook the Biomarkers of Lupus Disease study to test withdrawal of immunosuppressants as a novel approach to rendering SLE trials interpretable.
Methods. In 41 patients with active, non-organthreatening SLE flare (group A), temporary steroids were given while background immunosuppressants were withdrawn. Time to loss of disease suppression (time to disease flare) and safety were evaluated; standard therapy was immediately resumed when symptoms recurred. Immunologic impacts of standard therapy were studied at baseline by multiplex assay, enzymelinked immunosorbent assay, and messenger RNA array in group A patients plus 62 additional patients donating a single sample (group B).
Results. Patients with lower or higher baseline disease activity had median times to flare of 71 or 45 days, respectively; 40 of 41 patients (98%) had disease flares by 6 months. All flares were treated and resolved within 6 weeks. No serious adverse events occurred from flare or infection. Type I interferon (IFN), Th17, and B lymphocyte stimulator pathways tracked together. Baseline immunosuppressants had distinct impacts on Th17 and B lymphocyte stimulator, depending on IFN signature.
Conclusion. Trials in active, non-organ-threatening SLE can safely withdraw background treatments if patients who have disease flares are designated nonresponders and returned to standard therapy. Immunologic effects of standard therapy vary between IFN-defined subsets. These findings provide a strategy for minimizing or optimizing treatment combinations in lupus trials and clinical care. a common pathology have emerged (2, 3) , involving innate and adaptive immunity, defective immune clearance (4) (5) (6) (7) (8) (9) , and various combinations of multifactorial genetic risk variants (10, 11) . However, since patients may develop similar features via different routes in a circuitous and redundant immune system, it seems unlikely that any one treatment will work for all patients, and certainly not at a single dose.
The SLE field has seen only one approved treatment in 60 years and 25 years of disappointing clinical trial programs (12) (13) (14) (15) (16) (17) (18) (19) . Therefore, the predominant therapy for SLE remains empirical use of unapproved combinations of immunosuppressive agents that often fail to control disease adequately for long periods of time. Attempts to restore immunologic homeostasis with targeted biologic agents might be served by considering the complexity and heterogeneity of the patients. Current treatment development programs universally ignore this issue. With few exceptions (18) , most trials have failed to focus on subsets of patients with immunopathology even relevant to the mechanism being addressed. Still, exploratory analyses of ambiguous study results have repeatedly uncovered, after the fact, subgroups of patients for whom each treatment might have succeeded better (14) (15) (16) (17) (18) (19) .
Standard therapy varies greatly between patients. Most clinical trials in SLE are add-on studies, continuing whatever variegated background immunosuppressants and steroids are being taken at entry. This background polypharmacy obscures the interpretation of pharmacodynamic data and likely contributes to apparently high "placebo" response rates, which actually reflect standard therapy temporarily optimized by rescue regimens. Some recent trials have been marginally more successful by limiting the aggressiveness of rescue interventions while allowing patients to continue a variety of immunosuppressants (14) (15) (16) . However, suggestions to completely eliminate confounding background medications in SLE trials have been extremely controversial, even though patients have appreciable rates of serious infection when entering add-on trials with aggressive background medications.
In addition to obscuring pharmacodynamics and true response rates, background polypharmacy inevitably superimposes unknown immunomodulatory variables (14) (15) (16) (17) (18) (19) that could have synergistic, additive, or inhibitory impact on a treatment under study. However, the impact of standard therapy on the mechanistic pathways of targeted, investigational biologic agents has never been studied in SLE. It follows that the true degree of heterogeneity innate to SLE cannot be known until the impact of therapeutic cross-talk on immunologic variables is better defined.
To provide an avenue for addressing these knowledge gaps, the Biomarkers of Lupus Disease (BOLD) study was designed to test several hypotheses. First, if patients with active but not organ-threatening SLE are given temporary relief by steroid injections, withdrawal of background immunosuppressants can be accomplished safely. Second, improvement from intramuscular steroids will gradually wane, ensuring low response rates after a few months in the absence of additional effective treatment. Third, upon flare, patients can be designated nonresponders and treated immediately with reasonable safety. The BOLD study also sought to generate hypotheses based on gene expression and protein data that background treatments may have disparate effects on different patient immunophenotypes. If the above hypotheses are correct, then withdrawing standard therapy immunosuppressants in trials could also help eliminate potential interactions between investigational and background treatments that may confound characterization of patient pathology and impact the interpretability of trial results.
PATIENTS AND METHODS
Patient enrollment. This study was performed in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the Oklahoma Medical Research Foundation. Patients provided written informed consent prior to beginning study-specific procedures.
Patients in group A (n 5 41) completed both crosssectional and prospective substudies. Patients in group B (n 5 62) participated in the cross-sectional study only. Inclusion criteria for patients in groups A and B were as follows: fulfilling the American College of Rheumatology 1982 revised criteria for SLE (20) as updated in 1997 (21) ; receiving treatment with #20 mg prednisone (or equivalent) daily; having active, symptomatic disease despite standard therapy, defined as at least 2 British Isles Lupus Assessment Group (BILAG) B (moderate activity) scores (22) , or at least 1 BILAG A (severe activity) score or an SLE Disease Activity Index (SLEDAI) score of at least 6 (23); and having a clinical state warranting intervention equivalent to the steroids offered to patients in group A. Additional inclusion criteria for patients in group A were ability and willingness to stop any immunosuppressants (e.g., azathioprine, methotrexate, or mycophenolate mofetil). Exclusion criteria included active infection at screening, known previous HIV or hepatitis B or C infection, pregnancy or inadequate birth control in women of childbearing potential, cancer (except basal cell or cervical carcinoma) within 5 years, and any medical condition that would interfere with the protocol or compromise patient safety, including but not limited to the investigator's opinion of risk for organ-threatening disease.
Cross-sectional substudy. One hundred three patients with active SLE (groups A and B) underwent clinical assessments and provided blood specimens (at baseline). To improve interpretability of gene expression studies (see below), 55 healthy control subjects (group C) were matched to participants in either group A or group B by race, sex, and age (within 5 years) ( Table 1 ). Group C was used as a representative control population for scaling the principal component values and establishing normal gene expression ranges. Control subjects provided 2 samples at 2 different visits. High-quality samples from 99 of those visits were available for gene expression studies (see "Gene expression analysis" below).
Prospective substudy. After blood was obtained at baseline, group A patients discontinued immunosuppressants and received steroid injections (up to 640 mg methylprednisolone [MP] acetate within 2 weeks; maximum of 4 injections allowed). To continue in the study, patients had to demonstrate clinical improvement. Six patients required 640 mg, 19 required 480 mg, and 16 required #320 mg. Withdrawal of hydroxychloroquine at baseline was optional and could be overridden by patient or clinician. Patients taking low-dose oral steroids at entry continued at the same dose. Scheduled monthly disease activity assessments and adverse event collection were performed, and blood samples were obtained at each visit for safety monitoring, biomarker assessments, and coded storage in a repository. Upon clinical improvement (improving visit), patients were followed up monthly until disease activity increased (flare visit). As a safety strategy that is necessary for a trial of this design, patients were instructed to call or return to the clinic (without requiring an appointment) at any time they developed worsening symptoms. At the flare visit, standard therapy was reinitiated. Six patients with no improvement within 2 weeks of baseline were dropped from group A and immediately treated with standard therapy. Baseline samples from these patients, with their consent, were used in group B (final total of 41 patients in group A and 62 patients in group B).
Clinical assessments. We evaluated several measures at every visit. These included the hybrid SLEDAI, which is identical to the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) version of the SLEDAI (SELENA-SLEDAI) (24, 25) except for the proteinuria definition from the SLEDAI 2000 (26, 27) ; the SELENA-SLEDAI flare index with physician's global assessment of disease activity (24, 25) ; the BILAG 2004 index (28) ; the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) (29, 30) ; and tender and swollen joint counts. The SLEDAI and BILAG are commonly evaluated over the previous month (12) (13) (14) (15) (16) , but when patients improved within 2 weeks of the entry visit, a 2-week evaluation using SLEDAI and BILAG clinical templates was performed. In these cases, the BILAG definition requiring 2 weeks of improvement was modified to 1 week.
Clinical outcome measures. The primary end point was time to flare from baseline in group A patients (n 5 41), comparing patients with moderate disease at baseline (BILAG B score in #3 organs, no BILAG A score, and SLEDAI score #10) to those with significant disease (.3 BILAG B scores, at least 1 BILAG A score, SLEDAI score .10, or severe flare by clinical SELENA-SLEDAI flare index descriptors). KaplanMeier analysis and the log rank test were used to compare time to flare in the primary end point in subpopulations based on disease severity, steroid dose, and race.
Clinical improvement (improving visit) required clinician's opinion of significant improvement with no intention of increasing treatment, along with at least 1 grade of improvement by BILAG score in at least 1 organ or SLEDAI score decrease of at least 4 points. The flare visit was defined as clinician opinion of significant worsening and intention to treat, with at least 1 grade of worsening by BILAG score or a 4-point increase in SLEDAI score. The key secondary end point was a descriptive evaluation of adverse events.
Cytokine, chemokine, and soluble receptor measurement. Blood samples collected at baseline and at selected subsequent visits were assayed for levels of cytokines, chemokines, and soluble receptors. The Serum Analyte and Biomarker Core at the Oklahoma Medical Research Foundation uses a standardized xMAP 50-plex assay (Affymetrix/ eBioscience) on the BioPlex200 platform (Bio-Rad). This 2-laser immunobead multiplex technology quantifies 50 cytokines in 250 ml of plasma (31) . Serum B lymphocyte stimulator (R&D Systems) and APRIL (eBioscience) could not be multiplexed and were analyzed by enzyme-linked immunosorbent assay.
Gene expression analysis. Messenger RNA expression levels in whole blood samples were measured using TaqMan Low Density Arrays (Applied Biosystems) that included probe sets for 347 transcripts, and were then normalized to the median of endogenous control levels. Log 2 -scale gene expression (DC t ) values for 11 interferon (IFN)-related genes (GBP5, HERC5, IFI27, IRF7, ISG15, LY6E, MX1, OAS2, OAS3, RSAD2, and USP18) were mean-centered and then subjected to principal components analysis using R (32) . The first principal component (PC1) for each patient visit captured the majority of variance, providing a summarized expression measure for the 11 IFN-related genes. To make the arbitrary-scale PC1 values more interpretable, the DC t values from 99 healthy volunteer visits from which high-quality samples were available were projected onto the PC1, and PC1 values for both patients and healthy volunteers were scaled linearly, where PC1 values for healthy volunteer visits had a mean of zero and unit variance, determining an "IFN index." The mclust R package was used to fit a 2-Gaussian equal-variance mixture model to the IFN index to define a single dividing value to separate "IFN low" from "IFN high." Samples from each patient visit were classified as "IFN high" or "IFN low," and patients were classified as "IFN high" or "IFN low" based on the predominant visitlevel assignment. Gene expression data will be available at the NCBI GEO database (accession no. GSE92776) as of December 22, 2017. Statistical analysis. Relationships between gene expression, IFN group (high versus low expression of IFNinducible genes), and baseline immunosuppressants were examined using analysis of covariance with the covariates of RNA integrity number, assay batch, and percent neutrophils, based on our analysis of variable impacts. Relationships between protein concentrations (pg/ml), IFN group, and baseline immunosuppressants were evaluated using analysis of variance (ANOVA). For comparisons between subpopulations, gene expression and disease activity scores were analyzed by t-test, frequencies of autoantibody positivity by Fisher's exact test, and protein concentrations by ANOVA. Exploratory biomarker assessments were hypothesis-driven based on known pathology of SLE but were not adjusted for multiple comparisons.
RESULTS
Population. Participants were 91.3% women with a mean age of 41.3 years and were of Caucasian, African American, American Indian, and Asian race (Table 1) . Demographics were similar between groups, but group A had fewer American Indians ( Table 1 ). The mean 6 SD cumulative BILAG score was 15.2 6 5.73, and the mean 6 SD SLEDAI score was 8.8 6 3.73. Baseline lupus treatments included steroids, hydroxychloroquine, and immunosuppressants (32.1% azathioprine, 17.5% mycophenolate mofetil, 25.2% methotrexate) ( Table 2) . Overall, medications were comparable in groups A and B, with methotrexate slightly more common in group A and mycophenolate mofetil slightly more common in group B (Table 2) . More group B patients used steroids and had low levels of complement ( Table 2 ), suggesting that group B patients were sicker. However, disease activity scores did not differ between groups.
Changes in disease activity (group A). Supporting the clinician-weighted definitions of improvement and flare, scores on the BILAG 2004 index, SLEDAI, CLASI, and physician's global assessment of disease activity as well as joint counts decreased significantly at the improving visit and increased significantly at the flare visit for group A (P , 0.0001 in all cases except P , 0.0012 for the CLASI at the improving visit versus The prespecified primary end point was time to flare from baseline. All steroid injections were administered within the first 2 weeks of baseline. Within 6 months of baseline, 40 of the 41 group A patients exhibited flare, suggesting that analogous trials would have an extremely low placebo response rate at a 6-month milestone. Time to flare did not differ between patients grouped by a priori definitions of moderate (n 5 25; median 71 days) versus high (n 5 16; median 45 days) disease activity (P 5 0.44). However, in exploratory evaluations seeking prognostic indicators, time to flare was significantly shorter in patients with baseline cumulative BILAG scores of $17 compared to patients with scores of ,17 (P 5 0.029). African American patients exhibited flare sooner than other patients (P 5 0.013) (Figure 2) . Furthermore, flare occurred sooner in patients with BILAG scores of $17 who received #240 mg total MP acetate compared to those with BILAG scores of ,17 who received $320 mg total MP acetate (P 5 0.043). Thus, sicker patients requiring less MP acetate for an initial satisfactory response are likely to exhibit flares earlier than other patients, providing potentially useful parameters for clinical trial design (Figure 2 ). Use of low-dose steroids or antimalarials during the trial or withdrawal of different baseline immunosuppressants had no discernable impact on time to flare; however, this study was not powered to draw firm conclusions about these variables.
Safety. Adverse events were a prespecified, descriptive secondary end point. There were no adverse events in group B (single blood donation). Thirty-one adverse events were reported in group A; all resolved after evaluation and/or treatment. Nineteen adverse events were grade 1 or grade 2 infections. The two grade 3 adverse events (see Supplementary nonserious event (anal abscess that responded to oral antibiotics). Both patients recovered and remained in the study. There were no serious adverse events from lupus flare or infection.
As another safety measure, disease severity was compared between the baseline and flare visits in group A (see Supplementary Table 1 , http://onlinelibrary.wiley. com/doi/10.1002/art.40086/abstract). The percentage of patients with BILAG A scores (severe activity) did not differ between the baseline visit (29%) and the flare visit (29%). Five patients (12.2%) who entered with BILAG B scores (moderate activity) exited with BILAG A scores, and 5 patients (12.2%) who entered with BILAG A scores exited with BILAG B scores. No severe flares were organ-threatening; no flares involved nephritis, the central nervous system, serious hematologic features, or solid organs. One patient was followed up for 1 year and had no flare. All end-of-study flares were treated with standard therapy and resolved within 6 weeks.
SLE immunopathology. A large percentage of patients with SLE are characterized by an elevated type I IFN-inducible gene signature (8) , but it remains unclear whether IFN signals reliably discriminate optimal treatment groups. At baseline, patients in groups A and B with high type I IFN signals (IFN high) were compared to those without the signature (IFN low) ( Table 3) . IFNhigh patients displayed markedly higher gene expression of B lymphocyte stimulator (TNFSF13B; P 5 0.005) and interleukin-17 (IL-17) receptor A (IL17RA; P 5 0.009), confirming previous observations that activated B lymphocyte stimulator and IL-17 pathways are associated with type I IFN activity in SLE (7-9). IL23A gene expression was not increased in IFN-high patients. Protein levels of B lymphocyte stimulator (P 5 0.0001) and IL-23 (IL23p19) (P 5 0.01) were also higher in IFN-high patients. More IFN-high patients had antibodies to doublestranded DNA (P 5 0.0001), SSA/Ro (P 5 0.0007), RNP (P 5 0.0001), and Sm (P 5 0.01) ( Table 3) .
Impact of standard therapy on Th17 and B lymphocyte stimulator pathways in IFN-high and IFNlow patients. It has not been previously studied whether categorization of patients by IFN signatures could clarify understanding of standard therapy effects. Baseline IL17RA gene expression was modestly decreased in all (Table 4 ) (see Supplementary Figure 2 , http://onlinelibrary. wiley.com/doi/10.1002/art.40086/abstract). However, the impact of these medications was more evident when IFN-high and IFN-low patients were examined (Table 4) . Hydroxychloroquine treatment was associated with substantially lower TNFSF13B (B lymphocyte stimulator) gene expression in IFN-high patients, but not in IFN-low patients (Table 4) . Individual immunosuppressants had no consistent effects on protein or gene expression when comparing baseline visits (active disease, receiving treatment) and flare visits (not receiving treatment) in group A patients, but the numbers were small in each treatment group (data not shown). However, B lymphocyte stimulator RNA (but not protein) expression increased 2.4-fold from the baseline to the flare visit in all IFN-low patients, regardless of baseline treatments (P 5 0.0003), reaching levels equivalent to those seen in IFN-high patients (data not shown).
DISCUSSION
Data from the BOLD study suggest that future SLE clinical trials could achieve very low placebo response rates without unacceptably compromising patient safety by enrolling SLE patients with active, nonorgan-threatening disease, providing temporary steroids, and withdrawing standard therapy immunosuppressants. Risk of serious infections might even be reduced by eliminating excess immunosuppressants at baseline, but this study was not designed to test that hypothesis.
Most SLE clinical trials continue various, often effective standard therapy background medications being taken by patients at entry (12) (13) (14) (15) (16) (17) (18) (19) , based on assumptions that this minimizes risk of serious flares and that immunologic interference is minimal. However, these two assumptions are not evidence-based. Moreover, they are inconsistent with each other, since flares are only prevented by modulating immunologic pathways. In fact, data from trials indicate that patients receiving standard therapy alone have almost as many infections as those receiving standard therapy plus biologic agents (12) (13) (14) (15) (16) ; it therefore seems likely that standard therapy is at least as risky as some biologic agents. Other analyses suggest that in trials with a polypharmacy design, efficacy can only be distinguished in subsets of patients with higher grade disease activity (15, 16) . Since these patients are at highest risk of serious flares, it may be fortunate that interpretable studies can be performed for them without requiring treatment withdrawal.
Does this mean that clinical trials in SLE (and subsequent regulatory approvals) should be restricted to polypharmacy protocols in patients with the most severe disease? A recent shift in phase III plans for at least one agent (15) suggests that this notion is gaining traction, risking disenfranchisement of patients with chronic, moderate SLE from access to targeted biologic agents. There is a significant unmet need in this population, as even with good disease control, chronic, smoldering SLE leads to progressive organ damage, long-term morbidity, and mortality (33, 34) . Our data suggest that immunosuppressants can be safely withdrawn in these patients to support a safe and interpretable trial design. This approach might provide early proof of efficacy in less vulnerable patients while helping to define pharmacodynamic variables without confounding immunomodulatory signals. In turn, later trials with more vulnerable patients would be armed with better information to minimize risk of choosing untoward treatment combinations.
The need to account for confounding medications is highlighted by our exploratory observation that certain standard therapies might have unique effects on IFN-high patients versus IFN-low patients. Although they are used interchangeably in the clinic and in clinical trials, immunosuppressants may have disparate and even opposing effects in SLE subgroups; our preliminary observations support this hypothesis. If not addressed, this could confound clinical trials and selection of optimal treatment combinations in the clinic. Therefore, larger, prospective studies with prespecified biomarker end points and adjustments for multiple comparisons are needed to rigorously test the immunologic effects of antimalarials and immunosuppressants in different patient subsets. Our incidental finding that IFN-low patients exhibit uncharacteristically high B lymphocyte stimulator RNA expression at the time of acute flare also warrants further exploration. We previously described B lymphocyte stimulator as a robust marker for SLE disease activation (7), and various alternative immunologic routes can induce B lymphocyte stimulator (35) . Thus, B lymphocyte stimulator could represent a common pathway for discrete SLE subpopulations at the time of flare.
Given the heterogeneity of lupus, it is likely that exceptions to the broad themes inspected in this small study will arise, drawing attention to antagonistic or synergistic pathways in smaller patient subsets. However, better knowledge of the immunologic effects of standard therapy lupus medications on major identifiable subgroups of lupus will aid more rational testing and more successful use of targeted biologic agents.
